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Background. Tuberculosis causes significant morbidity and mortality worldwide, especially in sub-Saharan Africa. DC-SIGN,
encodedby CD209, is a receptorcapable of binding and internalizing Mycobacterium tuberculosis. Previous studies have reported
that the CD209 promoter single nucleotide polymorphism (SNP)-336A/G exerts an effect on CD209 expression and is associated
with human susceptibility to dengue, HIV-1 and tuberculosis in humans. The present study investigates the role of the CD209 -
336A/Gvariant insusceptibility to tuberculosisina largesampleofindividualsfromsub-SaharanAfrica.Methods andFindings. A
total of 2,176 individuals enrolled in tuberculosis case-control studies from four sub-Saharan Africa countries were genotyped for
the CD209 -336A/G SNP (rs4804803). Significant overall protection against pulmonary tuberculosis was observed with the -336G
allele when the study groups were combined (n=914 controls vs. 1262 cases, Mantel-Haenszel 2x2 x
2=7.47, P=0.006, odds
ratio=0.86, 95%CI 0.77–0.96). In addition, the patients with -336GG were associated with a decreased risk of cavitory tuberculosis,
a severe form of tuberculosis disease (n=557, Pearson’s 262 x
2=17.34, P=0.00003, odds ratio=0.42, 95%CI 0.27–0.65). This
direction of association is opposite to a previously observed result in a smaller study of susceptibility to tuberculosis in a South
African Coloured population, but entirely in keeping with the previously observed protective effect of the -336G allele.
Conclusion. This study finds that the CD209 -336G variant allele is associated with significant protection against tuberculosis in
individuals from sub-Saharan Africa and, furthermore, cases with -336GG were significantly less likely to develop tuberculosis-
induced lung cavitation. Previous in vitro work demonstrated that the promoter variant -336G allele causes down-regulation of
CD209 mRNA expression. Our present work suggests that decreased levels of the DC-SIGN receptor may therefore be protective
against both clinical tuberculosis in general and cavitory tuberculosis disease in particular. This is consistent with evidence that
Mycobacteria can utilize DC-SIGN binding to suppress the protective pro-inflammatory immune response.
Citation: Vannberg FO, Chapman SJ, Khor CC, Tosh K, Floyd S, et al (2008) CD209 Genetic Polymorphism and Tuberculosis Disease. PLoS ONE 3(1):
e1388. doi:10.1371/journal.pone.0001388
INTRODUCTION
Mycobacterium tuberculosis infection causes significant morbidity and
mortality throughout the world, particularly in resource-poor
countries. M. tuberculosis infects one third of the human population
and approximately two million persons die of tuberculosis every year
[1]. Over the next 20 years the WHO estimates that another billion
people will become newly infected with M. tuberculosis and more than
25 million will die from the disease, despite the availability of
antibiotics [2,3]. In sub-Saharan Africa, the rates of tuberculosis
range from 50 to greater than 300 per 100,000 individuals [2]. It is
now well-established that there is a host genetic component to
susceptibility to tuberculosis [4]. Evidence to support this includes the
observation of familial clustering of disease with higher concordance
of tuberculosis disease in monozygotic versus dizygotic twins [5], the
ethnic clustering of tuberculosis disease with a higher prevalence of
tuberculosis in individuals of recent African descent [6], as well as the
demonstration of both common polymorphisms and rare mutations
which confer susceptibility to mycobacterial species in humans [7].
Dendritic Cell-Specific ICAM3-Grabbing Non-integrin (DC-
SIGN), encoded by CD209 on chromosome 19p13.3, is a C-type
lectin that is expressed on subsets of dendritic cells (DCs) and
alveolar macrophages [8–10]. DC-SIGN has been demonstrated
to bind a variety of ligands [11]; endogenous ligands include
endothelial cells through ICAM-2, T-lymphocytes through
ICAM-3, neutrophils through MAC-1 and various endogenous
glycosylated structures [11–15]; exogenous ligands include glyco-
sylated moieties on M. tuberculosis, M. leprae, Bacillus Calmette-Gue ´rin
(BCG), Heliobacter pylori, Streptococcus pneumoniae, Klebsiella pneumoniae,
HIV-1, HIV-2, SIV-1, Dengue virus, Ebola Virus, Cytomegalo-
virus, Hepatitis C virus, Schistosoma mansoni, Leishmania pifanoi and
Candida albicans [10,16–28] (and reviewed in [29]).
DC-SIGN is a major receptor for M. tuberculosis on immune cell
subsets and hasbeen shown to bind mannosylated lipoarabomannan
(ManLAM) present on virulent, but not avirulent, strains of
Mycobacterium spp. [13]. This binding can lead to internalization of
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DC-SIGN may also have additional roles in suppressing Toll-like
receptor (TLR) signaling, thereby influencing Th1/Th2 balance
(proinflammatory/anti-inflammatory) and causing M. tuberculosis-
induced immune suppression [22,29]. This effect is mediated by
ManLAM and increased secretion of ManLAM from Mycobacteria
may be crucial to tuberculosis disease progression [29].
There has been considerable recent interest in the role of CD209
variation in human susceptibility to infectious diseases including M.
tuberculosis and M. leprae, HIV-1, and Dengue [18,30–32]. All but the
M. leprae case-control study found an association of the CD209 -
336A/G promoter SNP with infectious disease susceptibility or
protection. Martin and colleagues demonstrated that the -336G
allele wasassociated with susceptibility to parenteral but not mucosal
HIV-1 infection, although this was not replicated in individuals of
recent African descent [31]. Sakuntabhai and colleagues found that
the -336G allele was protective against Dengue fever versus Dengue
hemorrhagic fever, but not against controls [32]. Barreiro and
colleagues found an association between with the -871G and -336A
alleles and protection against tuberculosis in South African Cape
Coloureds, but not against leprosy in Pakistan [18,30]. Although the
CD209 -871 SNP was found to be the polymorphism most
significantly associated with tuberculosis susceptibility in the South
African Cape Coloureds, Barreiro and colleagues found that this
SNP is not polymorphic in other African countries. The relatively
high prevalence of the -871 SNP in the South African Cape
Coloureds cases and controls is due to their inherent admixture with
European and Asian populations.
Sakuntabhai and colleagues also presented evidence that the
CD209 -336G allele disrupts a potential SP-1-like transcription
factor binding site and that this allele is associated with lower
CD209 expression in vitro than the ancestral -336A variant [32].
On the basis of the importance of DC-SIGN in M. tuberculosis
binding and signaling events, and in an attempt to replicate the
findings of Barreiro and colleagues in a larger population, we
genotyped the CD209 -336A/G SNP in five tuberculosis case-
control studies from four different sub-Saharan African countries.
METHODS
Sample Information
The tuberculosis case control studies from The Gambia (A), Republic
ofGuineaandGuineaBissau[33],TheGambia(B)[34],andMalawi
[35] have been previously described in detail. Briefly, tuberculosis
case definitions for all studies depended upon confirmation of M.
tuberculosispositivity byculture, smear, or histology. HIV-1 testing was
routinely performed and the percentage of HIV-1 positive individuals
among the tuberculosis index cases and controls for the various
studies are as follows: The Gambia (A), cases 7.5%, controls 5.2%;
Republic of Guinea, cases 9.0%, controls 5.1%; Guinea Bissau, cases
23.8%, controls 16.2%; Malawi, cases 62.2%, controls 33.5%. The
Gambia (B) cohort has 330 confirmed HIV-1 negative tuberculosis
cases, with an additional 17 cases which were not tested for HIV-1
status. Controls for the various studies were defined as persons
without a previous history of tuberculosis and were frequency
matched for age, sex and area of residence. A number of clinical
correlates of tuberculosis were recorded for the The Gambia (A),
Republic of Guinea and Guinea Bissau studies including haemop-
tysis, duration of cough, degree of sputum positivity, and the presence
of cavitation and number of zones affected on chest radiograph.
Cavitory tuberculosis status and number of zones affected was
determined by radiological analysis by board-certified radiologists.
Informed written consent was obtained from patients or their
parents or guardians. Ethical approval was provided by the joint
Gambian Government/MRC Ethical Committee, Ministry of
Public Health (MINSAP, Guinea-Bissau) and National Ethics
Committee, Ministry of Health, Conakry, Republique de Guinee.
Human experimentation guidelines of these ministries were
followed. Ethical approval for the Malawi study protocol was
obtained from the National Health Sciences Research Committee
of Malawi and the London School of Hygiene and Tropical
Medicine Ethics Committee.
Genotyping techniques
DNA extraction from blood was performed using Nucleon II kits
(Scotlab Bioscience, Buckingham, UK). DNA concentrations were
determined using the PicoGreen
TM kit (Invitrogen, Carlsbad, USA).
Genotyping was performed utilizing the Sequenom
TM system
(Sequenom, San Diego, USA) which uses mass spectrometry
(MALDI-TOF) to discriminate products by their absolute mass
[36]. Primer extension was carried out utilizing a DNA primer
adjacent to the SNP, and a specific reaction mix of polymerase,
dNTPs and one ddNTPs. The extension products were then cleaned
up to remove salts and 15nl were spotted onto a 384 SpectroCHIP
(Sequenom). This chip was analysed by MALDI-TOF mass
spectrometer and the alleles called by weight (in kilodaltons) of the
extension products. The CD209 -871A/G (rs735239) and -336A/G
(rs4804803) SNP assays were designed using the SPECTRODESI-
GNER software (Sequenom). The primers for the CD209 -871A/G
were ACGTTGGATGCTCTGTCTGGGTCCTTTTAC, ACG-
TTGGATGACAGCAATGAAAAAGCAAAG, GCAAAGTACT-
AGTACATTTAATAAC and for CD209 -336A/G were ACGTT-
GGATGTGTTACACCCCCTCCACTAG, ACGTTGGATGA-
AAGCAGGAAAGCCAGGAGG, CCCTCCACTAGGGCAAG-
GGT. The assays were in 384-well plates containing 10 ng of
DNA in each well were amplified by a touch-down PCR using
Titanium Taq polymerase (Clontech). The touch-down PCR cycling
conditions were as follows: 95uCf o r1 5 m i n u t e s ;9 4 uCf o r
20 seconds; 65uC for 30 seconds; 72uC for 30 seconds; steps 2 to 4
repeated for 5 cycles; 94uC for 20 seconds; 58uC for 30 seconds;
72uC for 30 seconds; steps 5 to 7 repeated for 5 cycles; 94uCf o r
20 seconds; 53uC for 30 seconds; 72uC for 30 seconds; steps 8 to 10
repeated for 38 cycles; final extension at 72uCf o r3m i n u t e s .
Statistical analysis
Statistical analysis of genotype associations and logistic regression
was performed using the program SPSS v14.0. The genotypic and
allelic tests of association utilized Pearson’s chi-square test with the
respective degrees of freedom. All statistics are two-tailed. If the
unadjusted P value was significant then further analysis was
carried out using a stepwise forward binary logistic regression
correction to adjust for the potential confounding factors of HIV
status, age, ethnicity, and sex. Mantel-Haenszel for the combined
analysis was performed using SPSS by weighting cases by
frequency and stratifying by population. The Gambian (B) study
utilizes the Gambian (A) study controls for this Mantel-Haenszel
analysis. The Breslow-Day and Tarone’s tests for homogeneity of
odds ratios were found to be non-significant indicating that the
odds ratio for each study did not significantly deviate from the
overall, combined odds ratio. All control genotype distributions
were in Hardy-Weinberg equilibrium (P.0.20).
RESULTS
CD209 and association with tuberculosis
The CD209 -871A/G and -336A/G SNPs were initially genotyped
in 329 tuberculosis cases and 327 control individuals from The
Gambia (study group A) [33]. The CD209 -871 SNP was found to
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PLoS ONE | www.plosone.org 2 January 2008 | Issue 1 | e1388be polymorphic with controls and cases both having a 2.3% allele
frequency (allelic P=0.98) consistent with the Barreiro result [30]
and the HapMap project which found variation at this SNP to be
very rare to absent in individuals of African descent. The allelic
equivalence between cases and controls and the rarity of this SNP
precludedgenotypinginfurtherpopulations.FortheCD209-336A/
G SNP, however, an overall genotypic association with clinical
tuberculosis was observed for this cohort (3x2x
2=7.79, P=0.020)
(Table 1). The -336G allele was significantly under-represented in
tuberculosis cases (47.0%) when compared to healthy controls
(54.0%) (P=0.010, odds ratio of 0.75 (95%CI 0.61–0.94) (Table 2).
Logistic regression correction for age, sex, ethnic group and HIV-1
status did not significantly affect this association. Subsequently an
additional 347 tuberculosis cases from The Gambia were available
for genotyping (study group B), revealing a similar tuberculosis case
allele frequency (48.0%) and a significant association when analyzed
against the study group A control group [34].
Study groups from Republic of Guinea, Guinea-Bissau, and
Malawi were then used in an attempt to replicate this finding
[33,37].Eachstudy group, with the exception of Republic of Guinea
study, demonstrated the sametrend towards a protective effectof the
-336G allele. In total 2176 individuals were analyzed in this study
and combining the results in a Mantel-Haenszel test predicted a
protective effect of the -336G allele with an overall odds ratio of 0.86
(95%CI 0.77–0.96) and P=0.006 (Table 2). This allelic model
yielded a non-significant homogeneity of odds ratio between all the
study groups, (Tarone’s and Breslow-Day P=0.32), suggesting that
there was a good consistency between the combined odds ratio with
the individual odds ratios for each study.
Considering that HIV-1 status could potentially confound this
association we performed the Mantel-Haenszel test excluding all
individuals known to be HIV positive, giving an odds ratio of 0.83
(95%CI 0.73–0.94) and P=0.003 (Table S1). Although this
exclusion of HIV-infected individuals reduces the total sample size
of the study the conclusion remains unchanged.
CD209 and clinical correlates of tuberculosis
The CD209 -336A/G SNP was further examined in the cases for
association with clinical correlates of tuberculosis, with no
significant difference between sex, HIV status, age, haemoptysis,
number of zones affected on chest radiograph, duration of cough
or degree of sputum positivity. However, a significant association
was obtained between CD209 -336GG genotype status and lung
cavitation in tuberculosis patients. Patients homozygous for the
CD209 -336GG allele were associated with 2.4-fold protection
against cavitory tuberculosis disease (n=557, Pearson’s 262
x
2=17.34, P=0.00003, odds ratio=0.42, 95%CI 0.27–0.65,
PBonferroni corrected=1.19610
24)(Figure 1 and Table 3).
DISCUSSION
There is increasing evidence to support an important role for DC-
SIGN in the pathophysiology of a number of infectious diseases,
including M. tuberculosis infection.
Functional evidence suggests that the -336G variant has lower
basal expression of CD209 when compared to the -336A ancestral
allele [32]. Extrapolation of these in vitro experiments to in vivo
CD209 expression suggests that -336G individuals would have
lower levels of DC-SIGN on DCs and alveolar macrophages when
compared to -336A individuals. Barreiro and colleagues found an
association with the -336A allele and protection against tubercu-
losis and suggest that higher levels of DC-SIGN may be beneficial
in protection against tuberculosis disease.
Table 1. CD209 -336A/G SNP in Patients Enrolled in Tuberculosis Case Control Studies in Four Countries
..................................................................................................................................................
Variant The Gambia Republic of Guinea Guinea-Bissau Malawi
Cases (A) Cases (B) Controls Cases Controls Cases Controls Cases Controls
n=329 n=347 n=327 n=151 n=180 n=162 n=141 n=244 n=295
AA 26.7 28.0 22.0 28.3 29.8 32.7 25.5 43.5 38.3
AG 52.6 48.1 48.0 45.6 46.4 39.5 48.2 42.6 50.5
GG 20.7 23.9 30.0 26.1 23.8 27.8 26.3 13.9 11.2
x
2 7.79 4.66 – 0.24 – 2.71 – 3.45 –
P value 0.020 0.097 – 0.886 – 0.258 – 0.178 –
Genotypic frequency and genotypic association (362 x
2, 2 degrees of freedom) for CD209 -336A/G (rs4804803) from 2176 individuals enrolled in tuberculosis case
control studies from The Gambia (A), Republic of Guinea and Guinea-Bissau (ref. 33), The Gambia (B) (ref. 34) and Malawi (ref. 35). Significance level of P,0.05 is
indicated in bold.
doi:10.1371/journal.pone.0001388.t001
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Table 2. CD209 -336A/G SNP Allelic Association in Tuberculosis Case Control Studies
..................................................................................................................................................
Variant The Gambia (A) The Gambia (B)* Republic of Guinea Guinea-Bissau Malawi Overall (M-H)
G allele Controls 353 (54.0%) 353 (54.0%) 142 (47.0%) 142 (50.4%) 215 (36.4%) –
G allele Cases 309 (47.0%) 333 (48.0%) 176 (48.9%) 154 (47.5%) 172 (35.2%) –
Odds Ratio 0.75 0.79 1.08 0.89 0.95 0.86
95% CI 0.61–0.94 0.64–0.97 0.79–1.46 0.65–1.23 0.74–1.22 0.77–0.96
P value 0.010 0.028 0.632 0.488 0.684 0.006
The allelic P value for 2176 individuals enrolled in tuberculosis case control studies. The Gambia (A), Republic of Guinea and Guinea-Bissau (ref. 33), The Gambia (B) (ref.
34) and Malawi (ref. 35). *The Gambia (B) study utilizes The Gambia (A) controls. Significance levels of P,0.05 are indicated in bold.
doi:10.1371/journal.pone.0001388.t002
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PLoS ONE | www.plosone.org 3 January 2008 | Issue 1 | e1388Here we report studies of the CD209 -336A/G SNP in multiple
tuberculosis case control groups based in The Gambia, Republic
of Guinea, Guinea-Bissau, and Malawi. These studies, taken
together, reveal a genetic association with the -336G allele and
protection against tuberculosis. This protection was independent
of HIV-1 status as assessed by logistic regression as well as
removing all known HIV-1 cases from the analysis (Table S1).
These results differ from the Barrerio study [30]. This discrepancy
could reflect a chance finding in the original single study group,
since the confidence interval for this population overlaps with
those of our three smaller studies (Figure 2). Barreiro and
colleagues studied a South African Coloured population known to
have the -871 variant, which was absent in all of the sub-Saharan
African populations previously genotyped and very rare (,2.5%)
in this study. Indeed, it was the 2871 variant which showed the
most compelling evidence of association, with the 2336 variant
failing to reach even the nominal significance level of P=0.05 after
correcting for multiple testing. Due to the relative absence of the
2871 variant in the African populations genotyped in this present
study we could not ascertain the effect of this variant in
susceptibility to tuberculosis and it is entirely possible that the
2871/2336 haplotype drives differential CD209 expression
patterns but further work will be needed to confirm this.
Subgroup analysis suggested a significant association between
CD209 -336GG genotype status and protection against lung
cavitation. The potential role of DC-SIGN in cavitory tuberculosis
disease is novel and warrants further investigation. In this study we
are not able to distinguish between cavitory tuberculosis caused by
progression from primary infection, re-infection, or indeed by
canonical post-primary reactivation disease. Cavitory tuberculosis
in this setting defines a particularly severe manifestation of
tuberculosis. Pulmonary cavitation in tuberculosis is known to be
associated with the production of Th2 cytokines such as IL-4,
which have in turn been demonstrated to result in higher surface
expression levels of DC-SIGN in DCs [38–40]. This raises the
interesting question of whether individuals homozygous for the -
336G allele may, in part, be protected from expressing high levels
of DC-SIGN and therefore less prone to the Th2 shift induced by
ManLam binding to DC-SIGN [22,29,41,42].
Figure 1. CD209 -336GG and M. tuberculosis-induced lung cavitation.
This figure describes the percent of individuals with the CD209 -336GG
genotype who presented with cavitory tuberculosis disease.
doi:10.1371/journal.pone.0001388.g001
Table 3. CD209 -336A/G and Clinical Correlates of Tuberculosis
..................................................................................................................................................
Clinical Correlates Status CD209 -336A/G variant* Total P value Odds Ratio 95% CI
AA+AG GG
Sex Male 573 (73.4%) 208 (26.6%) 781 0.293 0.871 0.673–1.127
Female 389 (76.0%) 123 (24.0%) 512
HIV Negative 831 (73.8%) 295 (26.2%) 1126 0.255 1.306 0.823–2.073
Positive 92 (78.6%) 25 (21.4%) 117
Age Groups 0–19 100 (75.8%) 32 (24.2%) 132 0.996
20–29 363 (74.1%) 127 (25.9%) 490
30–39 264 (74.6%) 90 (25.4%) 354
40–49 145 (74.4%) 50 (25.6%) 195
50–99 90 (73.8%) 32 (26.2%) 122
Haemoptysis No 281 (77.2%) 83 (22.8%) 364 0.858 0.959 0.604–1.523
Yes 113 (77.9%) 32 (22.2%) 145
Cavitation No 194 (69.8%) 84 (30.2%) 278 0.0000313 0.421 0.278–0.636
Yes 236 (84.6%) 43 (15.4%) 279
No. Zones affected 1–3 182 (77.1%) 54 (22.9%) 236 0.931 0.982 0.658–1.468
4–6 247 (77.4%) 72 (22.6%) 319
Duration of cough 0–8 weeks 271 (79.0%) 72 (21.0%) 343 0.259 1.285 0.831–1.989
.8 weeks 123 (74.5%) 42 (25.5%) 165
Degree of sputum positivity + 12 (66.7%) 6 (33.3%) 18 0.604
++ 162 (75.7%) 52 (24.3%) 214
+++ 337 (76.8%) 102 (23.2%) 439
*Combined West African tuberculosis case control data. Significance level of P,0.05 is indicated in bold.
doi:10.1371/journal.pone.0001388.t003
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PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1388Maturation of DCs, defined by DC upregulation of co-
stimulatory molecules such as CD80/CD86, can occur on
exposure to TLR ligands. This process can however be inhibited
by a variety of unknown mechanisms. One possible mechanism of
inhibition of DC maturation is the binding of pattern recognition
receptors to molecular patterns present on host cells [43]. This
process, in theory, would cause DC anergy and a reduction in the
pro-inflammatory response, even in the presence of pathogen-
associated molecular patterns. Virulent Mycobacterium spp. have
evolved mechanisms to more heavily decorate the cell wall
lipoglycoconjugates with a(1R2) mannosylated termini which
closely resemble the high mannose N-linked oligosaccharides of
newly produced glycoproteins in eukaryotic cells [44]. Perhaps this
molecular mimicry could be part of the mechanism by which
virulent strains of M. tuberculosis modulate the immune response. If
so, DC-SIGN is a prime target for this virulence strategy.
Overall, our results suggest that lower levels of DC-SIGN on
immune subsets may be protective against tuberculosis in the sub-
Saharan Africa setting. The findings implicate the involvement of
DC-SIGN in the pathogenesis of clinical tuberculosis in general,
and severe, cavitory tuberculosis in particular. This has wider
implications since it provides further evidence that M. tuberculosis
may use the DC-SIGN receptor to subvert the immune response.
SUPPORTING INFORMATION
Table S1 CD209-336A/G SNP Allelic Association in Tubercu-
losis Case Control Studies Excluding All HIV-1 Positive Cases and
Controls. The allelic P value for HIV-1 negative individuals
enrolled in tuberculosis case control studies. The Gambia (A),
Republic of Guinea and Guinea-Bissau (ref. 33), The Gambia (B)
(ref. 34) and Malawi (ref. 35). *The Gambia (B) study utilizes The
Gambia (A) controls. Significance levels of P,0.05 are indicated in
bold.
Found at: doi:10.1371/journal.pone.0001388.s001 (0.06 MB
DOC)
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